REG - Oncimmune Hldgs PLC - Block Listing Return

Oncimmune HoldingsAnnouncement

13/03/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240313:nRSM7651Ga&default-theme=true

RNS Number : 7651G  Oncimmune Holdings PLC  13 March 2024

13 MARCH 2024

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Block Listing Return

 

 

 Name of applicant:                                                          Oncimmune Holdings plc

 Name of scheme:                                                             Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans

 Period of return:                                                           15 March 2022 to 12 March 2024

 Balance of unallotted securities under scheme(s) from previous return:      5,787,346

 Plus: The amount by which the block scheme(s) has been increased since the  0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period:   108,882

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:   5,678,464

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com

 

Singer Capital Markets (Nominated Adviser and Broker)

Philip Davies, Harry Gooden, James Fischer

+44 (0)20 7496 3000

 

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREAXDDFAPLEFA